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1.25 (3H, t, J = 7.6 Hz); 13 C NMR (CDCl 3 ) δ: 161.6, 157.2, 147.5, 135.1, 134.7, 132.8, 130.7, 130.1, 128.2, 127.12, 127.10, 126.7, 120.6, 28.7, 10.8; MS (m/z) 
3-(2-Bromophenyl)-2-ethylquinazolin-4(3H)-one (1c). 1c was prepared from
2-bromoaniline (559 mg, 3.25 mmol) and N-propionyl anthranilic acid (483 mg, 2.5 mmol) in accordance with the procedure for the synthesis of 1a. Purification of the residue by column chromatography (hexane/AcOEt = 3) gave 1c (611 mg, 74% 2.35 (1H, qd, J = 7.6, 16.4 Hz), 1.26 (3H, t, J = 7.6 Hz); 13 C NMR (CDCl 3 ) δ: 161.6, 157.0, 147.6, 136.7, 134.6, 133.9, 130.8, 130.1, 128.9, 127.2, 127.1, 126.6, 123.2, 120.7, 28.8, 10.8 
3-(2-Iodophenyl)-2-ethylquinazolin-4(3H)-one (1d). 1d was prepared from 2-iodoaniline
(438 mg, 2.5 mmol) and N-propionyl anthranilic acid (386 mg, 2.0 mmol) in accordance with the procedure for the synthesis of 1a. Purification of the residue by column chromatography (hexane/AcOEt = 4) gave 1d (564 mg, 75%). 1d: white solid; mp 171-174 °C; IR (neat) 1682 cm -1 ; 8.29 (1H, dd, J = 0.8, 6.8 Hz), m) 161.8, 157.9, 147.7, 136.4, 135.6, 134.5, 131.5, 129.5, 128.2, 127.5, 127.1, 127.0, 126.5, 120.7, 28.9, 17.5, 11.0; MS (m/z) 1, 158.0, 147.7, 140.9, 135.8, 134.4, 129.7, 129.3, 128.3, 127.3, 127.1, 127.0, 126.5, 120.7, 28.9, 23.6, 13.5, 11.0; MS (m/z) 1, 147.6, 145.8, 134.8, 134.4, 129.9 128.2, 127.2, 127.1, 127.0, 126.5, 120.7, 29.0, 28.2, 24.2, 23.0, 11.0; MS (m/z) 1, 147.4, 135.3, 134.7, 133.5, 130.9, 129.9, 127.90 161.8, 159.8, 147.7, 136.7, 135.5, 134.6, 133.8, 130.7, 128.6, 127.3, 127.0, 126.5, 123.3, 120.6, 117.2, 40.4, 37.9, 18.9 160.0, 147.6, 136.6, 136.2, 134.6, 133.9, 130.8, 130.2, 128.7, 127.3, 127.1, 126.6, 123.3, 120.6, 117.0, 39.1, 38.0, 19.4 
(P*,S*) and (P*,R*) 3-(2-Chlorophenyl)-2-(pent-4-en-2-yl)quinazolin-4(3H)-one (2b and
2b'). 2b and 2b' were prepared from rac-1b (85 mg, 0.3 mmol) and ally bromide (54 mg, 0.45 mmol) in accordance with the procedure for synthesis of 2c and 2c'. Purification of the residue by column chromatography (hexane/AcOEt = 4) gave the mixtures of 2b and 2b' (94 mg, 96 %). The diastereomer ratio of 2b and 2b' (4. 159.9, 147.7, 135.6, 135.1, 134.6, 133.0, 130.8, 130.7, 130.6, 128.0, 127.3, 127.0, 126.5, 120.6, 117.2, 40.3, 37.9, 19.0 161.8, 159.9, 147.7, 136.1, 135.0, 134.6, 132.9, 130.70, 130.68, 130.2, 128.1, 127.3, 127.0, 126.6, 120.6, 116.9, 39.1, 38.0, 19.4 
(P*,S*) and (P*,R*) 3-(2-Iodophenyl)-2-(pent-4-en-2-yl)quinazolin-4(3H)-one (2d and 2d').
2d and 2d' were prepared from rac-1d (113 mg, 0.3 mmol) and allyl bromide (54 mg, 0.45 mmol) in accordance with the procedure for synthesis of 2c and 2c'. Purification of the residue by column chromatography (hexane/AcOEt = 4) gave the mixtures of 2d and 2d' (106 mg, 85 %). The diastereomer ratio of 2d and 2d' (17.9:1) was determined on the basis of 127.17, 127.0, 126.4, 120.7, 117.1, 40.2, 37.5, 18.8, 17.6; MS (m/z) 147.8, 136.2, 135.8, 134.4, 131.4, 129.4, 128.2, 127.23, 127.18, 127.0, 126.4, 120.7, 117.1, 39.3, 38.2, 20.0, 17.8 2, 8.8 Hz), m), m), 7.38 (1H, m), 7.19 (1H, d 160.6, 147.8, 141.1, 135.65, 135.60, 134.4, 129.6, 129.2, 128.8, 127.2, 127.0, 126.4, 120.7, 117.1, 40.3, 37.4, 23.5, 18.6, 13.5; MS (m/z) 134.4, 129.6, 129.0, 128.3, 127.2, 127.1, 127.0, 126.4, 120.7, 117.1, 39.2, 38.0, 23.4, 19.9, 13. 162.4, 160.7, 147.7, 146.0, 135.5, 134.7, 134.3, 129.8, 128.7, 127.1, 126.9, 126.4, 120.7, 117.1, 40.4, 37.3, 28.1, 24.5, 22.8, 18.4 162.5, 159.8, 147.5, 135.2, 134.6, 133.2, 131.3, 127 .94 (q, J C-F = 30.5 Hz), 127.87 (q, J C-F = 4.8 Hz), 127.2, 126.9, 126.6, 122.8 (q, 120.3, 117.3, 40.6, 37.9, 17 
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